Trial Profile
A double blind multiple ascending dose phase I study of RV-521 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2017
Price :
$35
*
At a glance
- Drugs Sisunatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 06 Sep 2017 New trial record